298681-10-4

Basic information

• Product Name: 1-Pyrrolidinecarboxylic acid, 3,4-dihydroxy-, 1,1-dimethylethyl ester
• CAS NO: 298681-10-4
• Molecular Formula: C9H17NO4
• Molecular Weight: 203.238
• Mol File: 298681-10-4.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 1-Pyrrolidinecarboxylic acid, 3,4-dihydroxy-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Pyrrolidinecarboxylic acid, 3,4-dihydroxy-, 1,1-dimethylethyl ester(298681-10-4)
• EPA Substance Registry System: 1-Pyrrolidinecarboxylic acid, 3,4-dihydroxy-, 1,1-dimethylethyl ester(298681-10-4)

Safety Data

• Hazardous Substances Data: 298681-10-4(Hazardous Substances Data)

Usage

Chemical classification

A naturally occurring organic compound.

Essential role

Vital for growth and repair of tissues in the body.

Antioxidant properties

Powerful antioxidant that protects cells from damage caused by free radicals.

Collagen production

Involved in the production of collagen, a protein important for skin, cartilage, and blood vessel health.

Dietary supplement use

Commonly used to prevent and treat vitamin C deficiency.

Cardiovascular health benefits

Potential benefits for cardiovascular health.

Chronic disease risk reduction

May help to reduce the risk of certain chronic diseases.

Upstream product

• 73286-70-1 N-(tert-butoxycarbonyl)-3-pyrroline 
• 86953-79-9 tert-butyl pyrrolidine-1-carboxylate 
• 114214-49-2 1-tert-butoxycarbonyl-3,4-epoxypyrrolidine 

Relevant articles and documents

COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES

The present invention provides a compound of formula (Ia) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, solid forms, combinations of pharmacologically active agents, pharmaceutical compositions and methods of using such compounds and solid forms thereof to treat or prevent parasitic diseases, for example malaria.

N-Bridged bicyclic sulfonamides as inhibitors of γ-secretase

The structural modification of a series of [3.3.1] bicyclic sulfonamide based γ-secretase inhibitors is described. Appropriate substitution on the bicyclic scaffold provides a significant increase in the metabolic stability of the compounds resulting in an improved in vivo metabolic profile.

QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS

The invention concerns quinazoline derivatives of Formula (I): (A chemical formula should be inserted here - please see paper copy enclosed herewith) wherein Z is an O, S, SO, SO2, N(R2) or C(R2)2 group wherein each R2 group is hydrogen or (1-8C) alkyl, m is 0, 1, 2 or 3, each R1 group is selected from halogeno, (1-8C) alkyl, (1-6C) alkoxy and any of the other meanings defined in the description, n is 0, 1, 2 or 3, and each R3 group is selected from halogeno, (1-8C) alkyl, (1-6C) alkoxy and any of the other meanings defined in the description, or pharmaceutically-acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.